According to a Fierce Biotech report, Sanofi has inked a deal with Harvard to collaborate on translational biomedical research focused in the therapeutic areas of cancer, inflammation and diabetes. Sanofi continues to explore new research models and collaborations in an effort to boost revenues due to expected shortfalls due approaching patent expirations on key drugs.
The funded projects will be selected by a Joint Scientific Steering Committee made up of members from Harvand and Sanofi. The awards will help Harvard researcher gain quick financial support for the development of innovative solutions in areas of high patient need. Sanofi will have the opportunity to develop diagnostic, therapeutic and prognostic applications from these discoveries.
"Our relationship with Harvard underscores sanofi-aventis' approach of leveraging our innovative internal resources while actively engaging a range of external partners to develop healthcare solutions," said Marc Cluzel, M.D., PhD, Executive Vice-President, Research & Development, Sanofi.
Ok, so it was MIT not Harvard in movie - poetic license.
Posted by Bruce Lehr October 18th 2010.
Comments